Literature DB >> 26950887

Management of endobronchial tumors.

Stefano Gasparini1, Martina Bonifazi.   

Abstract

PURPOSE OF REVIEW: Owing to the high morbidity and mortality rates related to airways obstruction, an effective management of endobronchial tumors is essential to improve survival and symptoms in these patients. As interventional pulmonology plays a major role in this context, the purpose of the present review is to focus on current evidence and indications of therapeutic bronchoscopy, in particular of ablative techniques. RECENT
FINDINGS: Several ablative techniques are currently available and include 'immediate' or 'delayed' procedures according to the expected time to restore airways patency. In case of critical lesions, it is mandatory to promptly restore ventilation through the immediate techniques, whereas the delayed approaches, with a prolonged effect, should be reserved for a nonemergency setting, according to clinical and prognostic factors. Recent data confirmed that almost every technique, in experienced hands, when the specific indications are met, is highly effective in restoring airways patency, with a valuable risk-benefits profile.
SUMMARY: Owing to the complex heterogeneity of different clinical settings, management of endobronchial tumors requires a multimodal approach to assess the best strategy. Despite the lack of high-quality prospective studies comparing the individual techniques or strategy, it is undisputed that therapeutic bronchoscopy should not be considered as a last resort, but rather as a key step of such multimodal management.

Entities:  

Mesh:

Year:  2016        PMID: 26950887     DOI: 10.1097/MCP.0000000000000259

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  1 in total

1.  Endobronchial lesions cases treated with interventional bronchoscopic techniques: Our single-center experiences.

Authors:  Ahmet Ulusan; İbrahim Emre Tunca; Maruf Şanlı; Ahmet Feridun Işık
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-04-22       Impact factor: 0.332

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.